| Iupac Name: | (1R,18R,20R,24S,27S,28S)-N-[(1''R'',2''R'')-2-(Difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-24-(2-methyl-2-propanyl)-22,25-dioxo-2,21-dioxa-4,11,23,26-tetraazapentacyclo[24.2.1.0<sup>3,12</sup>.0<sup>5,10</sup>.0<sup>18,20</sup>]nonacosa-3(12),4,6,8,10-pentaene-27-carboxamide| image = Voxilaprevir.svg| alt =| caption =| pronounce =| tradename = Vosevi (combination with sofosbuvir and velpatasvir)| Drugs.com =| MedlinePlus =| licence_EU =| licence_US =| pregnancy_AU = | pregnancy_AU_comment =| pregnancy_US = | pregnancy_category =| routes_of_administration =| legal_AU = | legal_AU_comment =| legal_CA = | legal_DE = | legal_NZ = | legal_UK = | legal_US = | legal_UN = | legal_status = | bioavailability =| protein_bound =| metabolism =| metabolites =| onset =| elimination_half-life =| duration_of_action =| excretion =| CAS_number = 1535212-07-7| PDB_ligand = L9P| class =| ATCvet =| ATC_prefix = | ATC_suffix =| PubChem = 89921642| DrugBank =| ChemSpiderID = 44209500| UNII = 0570F37359| KEGG = D10899| C = 40 | H = 52 | F = 4 | N = 6 | O = 9 | S = 1| smiles = CC[C@@H]1[C@@H]2CN([C@@H]1C(=O)N[C@@]3(C[C@H]3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)[C@@H](NC(=O)O[C@@H]5C[C@H]5CCCCC(c6c(nc7cc(ccc7n6)OC)O2)(F)F)C(C)(C)C| StdInChI = 1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1| StdInChIKey = MZBLZLWXUBZHSL-FZNJKFJKSA-N| density = 1.4±0.1[1] | Jmol=None}} Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir.[2] The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.[3] On 18 July 2017, Vosevi was approved by the US Food and Drug Administration.[4] References |